The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2021 Jan 26

DOI: 10.23736/S1824-4785.21.03291-X

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Practice and prospects for PET/CT guided interventions

Mateos BOGONI ¹, Juliano J. CERCI ¹, Francois H. CORNELIS ², Cristina NANNI ³, Elena TABACCHI ³ , Heiko SCHȌDER ⁴, Paul B. SHYN ⁵, Constantinos T. SOFOCLEOUS ⁶, Stephen B. SOLOMON ⁶, Assen S. KIROV ⁷ ✉

¹ QUANTA-Diagnóstico e Terapia, Curitiba, Brazil; ² Sorbonne Université / APHP, Tenon Hospital, Paris, France; ³ Nuclear Medicine, S. Orsola-Malpighi Hospital, Bologna, Italy; ⁴ Nuclear Medicine, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁵ Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; ⁶ Interventional Radiology, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁷ Molecular Imaging and Therapy Physics, Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

During the past 10 years, performing real-time molecular imaging with positron emission tomography (PET) in combination with computed tomography (CT) during interventional procedures has undergone rapid development. Keeping in mind the interest of the nuclear medicine readers, an update is provided of the current workflows using real-time PET/CT in percutaneous biopsies and tumor ablations. The clinical utility of PET/CT guided biopsies in cancer patients with lung, liver, lymphoma, and bone tumors are reviewed. Several technological developments, including the introduction of new PET tracers and robotic arms as well as opportunities provided through acquiring radioactive biopsy specimens are briefly reviewed.

KEY WORDS: PET/CT; Biopsy; Ablation